Enoch Chang

Dr @Ansel_PhD at #ASTRO24 on how to better design a clinical trial. If we want our trials to succeed, we should carefully consider how to power them as control arm overperformance is highly prevalent and associated with lower odds of a positive primary endpoint.

Our @MDAndersonNews PGY4 resident @StephDudzinski presents study evaluating genomic&path features a/w outcome for SLN+ melanoma pts. No assoc btwn dz outcomes &TERT/ATRX or BRAF mutations but adverse path features=badness.Clinical trial ongoing.Fantastic work! #ASTRO24 @ashleighg

Promising initial results of IMMUNOCERV vaccine study in cervical cancer reported by ⁦@adam_grippin⁩ from ⁦@MDAndersonNews⁩. #endcancer #radonc

Remarkable innovation by another stellar resident @MDAndersonNews @BenjaminSchrank in @wenjiang_nano lab to enhance anti-tumor immunity through a novel macrophage targeting ADC!! @ACKoongMDPhD @ChelseaPinnix

What are the biological mechanisms after SABR vs SABR plus IO in early stage NSCLC? Our talented resident @ASeoMDPhD presented different dynamic immunological cytokines profiles in our I-SABR randomized study @MDAndersonNews

Cullen would be so proud of you @Vince_BernPag You are a masterful science communicator just like he was. ❤️

Congratulations to @MDAndersonNews #RadOnC resident @dr_p_carriere for an outstanding presentation on the 2ndary analysis of the 1,656 low risk prostate cancer pts enrolled on the CEASAR study. Job well done!

Thank you Dr. Gibbs for joining us here at @MDAndersonNews as a visiting professor! What a privilege to learn from such an inspiring trailblazer in the field

Truly honored to cap off the @AACR @ASCO Clinical Trial Workshop with the award for Most Innovative Protocol! Huge thank you to workshop faculty, many new friends, and leadership @MDAndersonNews for supporting this incredible week!

Congrats @ebludmir and @ChadTangMD! This @MDAndersonNews P2 randomized study shows PFS of 10.3 mo vs. 2.5 mo in #PancreasCancer pts with oligometastatic dz treated with metastasis-directed therapy+sys tx vs. sys tx alone. #radonc #endcancer ascopubs.org/doi/10.1200/JC…

Superstar⁩ #radonc resident, ⁦@lee_kamaria⁩, presents results of impact of mobile health technology on health outcomes in Sub-Saharan Africa. ⁦Data presented @MDAndersonNews⁩ and Cancer Diseases Hospital Joint Symposium in #Zambia.

Response-adapted RT led to complete resolution of orbital disease in 90% of patients @ChelseaPinnix @BouthainaDabaja #radonc jamanetwork.com/journals/jamao…

Our new research highlights patient-level savings using the Mark Cuban Cost Plus Drug Company (MCCPDC) for purchasing generic drugs! This is the first study to quantify individual out-of-pocket savings by opting for MCCPDC over traditional insurance. jamanetwork.com/journals/jama-…

NEW: Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT #lymphoma: a single-centre, pilot trial @MDAndersonNews #lymsm thelancet.com/journals/lanha…

Congratulations @TaniguchiMD - I know how incredibly proud you are of this @TheLancetOncol study out today. Your paper made the cover highlight! This was Cullen’s baby from the very preclinical inception in his lab, and it breaks my heart that I can’t shake his hand in person. Stereotactic body radiotherapy with or without selective dismutase mimetic in #PancreaticCancer: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. thelancet.com/journals/lanon… Cc: @ACKoongMDPhD @PrajnanDasMD @colbertle @aguilera_md @DrShubhamPant @Vince_BernPag @ebludmir @eugenekoay

1/ 🔬🧫Tumoral lactic acid bacteria can rewire tumor metabolism and drive cancer treatment response. Our @cancercell paper is finally out #openaccess online! 🦠🔬 tinyurl.com/56puk8bx

Still reeling from the news about @TaniguchiMD . He was the best of us. A remarkable soul whose selflessness and kindness touched many, myself included. CT loved a good tweetorial, so in seeking words, I'll share memories of him. #RememberingCT

Randomized study published in Lancet today, showing 62% EFS improvement with Nivo + SABR compared with SABR alone in early stage NSCLC. I-SABR is a promising TX option. awbs://authors.elsevier.com/c/1hRV5V-4XL3dJ @IASLC @MDAndersonNews @TheLancet @ACKoongMDPhD @StephenVLiu

Happy #MatchDay2021‼️ Congrats and welcome 🙌🏼 @MDAndersonNews #radonc #residency #Classof2026 to the #workfam ☢️💛 @ChelseaPinnix @DrEmmaHolliday @StephDudzinski @RKouzyMD @adam_grippin @Enoch_Chang @cd_fuller @TaniguchiMD